دورية أكاديمية
أعرض في EDS

A comparison of anti-cyclic citrullinated peptides (CCP3 and CCP3.1) autoantibody tests in rheumatoid arthritis.

التفاصيل البيبلوغرافية
العنوان: A comparison of anti-cyclic citrullinated peptides (CCP3 and CCP3.1) autoantibody tests in rheumatoid arthritis.
المؤلفون: Nelson HA; ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA.; Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA., Banerjee D; ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA., Novis CL; ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA., Deane KD; University of Colorado School of Medicine Anschutz Medical Campus, Aurora, CO, USA., Feser ML; University of Colorado School of Medicine Anschutz Medical Campus, Aurora, CO, USA., Nandakumar V; ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, UT, USA.; Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT, USA.
المصدر: Practical laboratory medicine [Pract Lab Med] 2024 Jul 21; Vol. 41, pp. e00420. Date of Electronic Publication: 2024 Jul 21 (Print Publication: 2024).
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101690848 Publication Model: eCollection Cited Medium: Print ISSN: 2352-5517 (Print) Linking ISSN: 23525517 NLM ISO Abbreviation: Pract Lab Med Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: [Amsterdam] : Elsevier B.V., [2015]-
مستخلص: Background: Anti-citrullinated protein antibodies (ACPA) are a specific serological biomarker used in the diagnosis of rheumatoid arthritis (RA). In clinical practice ACPA can be identified using immunoassays targeting synthetic cyclic citrullinated peptides (CCP). The 3rd generation anti-CCP IgG antibody (CCP3) offers improved sensitivity compared to the earlier versions. Recently, CCP3.1, capable of detecting both IgG and IgA antibodies, was introduced to enhance sensitivity, especially in patients with early RA.
Methods: We assessed serum CCP3.1 against CCP3 in 331 subjects undergoing RA panel serology, comprising 136 patients with RA and 195 patients without RA. Sera were tested for anti-CCP IgG (CCP3) and anti-CCP IgG/IgA (CCP3.1) antibodies. Clinical performance of these tests was compared at manufacturer-suggested cutoffs. A separate set of 81 patients with a diagnosis of RA by 2010 criteria and whose samples were obtained from within 1-year of RA diagnosis was similarly assessed to evaluate assay performance in an independent clinical RA cohort.
Results: Overall diagnostic accuracy was similar; CCP3 had an area under the curve (AUC) of 0.88, CCP3.1 had an AUC of 0.89. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) for CCP3 were 79 %, 91 %, 86 %, and 86 %, respectively. For CCP3.1, sensitivity was 78 %, specificity 93 %, PPV 89 %, NPV 86 %. Both assays demonstrated excellent agreement; positive percent agreement of 94 % and negative percent agreement of 99 %.
Conclusion: Our findings indicate comparable diagnostic accuracy between CCP3 and CCP3.1 assays in these clinical cohorts.
Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2024 The Authors.)
References: Ann Intern Med. 2010 Apr 6;152(7):456-64; W155-66. (PMID: 20368651)
Arthritis Rheum. 2000 Jan;43(1):155-63. (PMID: 10643712)
J Rheumatol. 2010 Aug 1;37(8):1582-8. (PMID: 20516016)
Radiology. 1983 Sep;148(3):839-43. (PMID: 6878708)
Arthritis Rheum. 2009 Aug;60(8):2232-41. (PMID: 19644872)
Clin Chem. 2001 Jun;47(6):1089-93. (PMID: 11375296)
Clin Chim Acta. 2007 Nov-Dec;386(1-2):76-81. (PMID: 17826752)
Arthritis Rheum. 2006 Dec;54(12):3799-808. (PMID: 17133560)
Arthritis Rheum. 2009 Nov 15;61(11):1472-83. (PMID: 19877103)
Nat Rev Rheumatol. 2022 Oct;18(10):591-602. (PMID: 36068354)
Front Immunol. 2023 Jan 05;13:1096866. (PMID: 36685579)
Autoimmune Dis. 2011;2011:815038. (PMID: 21915375)
Stat Med. 1985 Apr-Jun;4(2):213-26. (PMID: 4023479)
Arthritis Rheum. 2013 Sep;65(9):2243-52. (PMID: 23686569)
Arthritis Res Ther. 2011 Feb 03;13(1):R13. (PMID: 21291540)
Front Immunol. 2018 Apr 24;9:876. (PMID: 29740454)
Scand J Rheumatol. 2013;42(2):108-14. (PMID: 23126558)
Clin Rev Allergy Immunol. 2008 Feb;34(1):21-5. (PMID: 18270853)
Ann Rheum Dis. 2005 Oct;64(10):1510-2. (PMID: 15800005)
Arthritis Res Ther. 2008;10(4):R75. (PMID: 18601717)
Clin Chem. 2007 Aug;53(8):1527-33. (PMID: 17586589)
Clin Chem. 2007 Mar;53(3):498-504. (PMID: 17259232)
Ann Rheum Dis. 2008 Apr;67(4):542-6. (PMID: 17644546)
Clin Chem Lab Med. 2014 Jun;52(6):779-90. (PMID: 24445240)
Int J Rheum Dis. 2016 Sep;19(9):880-6. (PMID: 25940989)
Clin Lab Sci. 2008 Winter;21(1):15-8. (PMID: 18335856)
Biometrics. 1977 Mar;33(1):159-74. (PMID: 843571)
Clin Chim Acta. 2012 Dec 24;414:266-72. (PMID: 23022338)
Clin Rheumatol. 2009 Feb;28(2):153-8. (PMID: 18795390)
Clin Med (Lond). 2020 Nov;20(6):561-564. (PMID: 33199320)
Clin Rev Allergy Immunol. 2007 Feb;32(1):47-56. (PMID: 17426360)
معلومات مُعتمدة: P30 AR079369 United States AR NIAMS NIH HHS
فهرسة مساهمة: Keywords: Cyclic citrullinated peptide antibodies; Diagnostic performance; Rheumatoid arthritis
تواريخ الأحداث: Date Created: 20240820 Latest Revision: 20240914
رمز التحديث: 20240914
مُعرف محوري في PubMed: PMC11332063
DOI: 10.1016/j.plabm.2024.e00420
PMID: 39161944
قاعدة البيانات: MEDLINE
الوصف
تدمد:2352-5517
DOI:10.1016/j.plabm.2024.e00420